Obstetrics & Gynaecology · Antepartum and Postpartum Hemorrhage

The WOMAN trial assessed tranexamic acid administration for PPH. Which of the following best describes the trial's main finding regarding mortality?

  • A Tranexamic acid significantly reduced death from bleeding when given within 3 hours of delivery
  • B Tranexamic acid significantly reduced all-cause maternal mortality
  • C Tranexamic acid increased thromboembolic events and was not recommended
  • D Tranexamic acid reduced hysterectomy rates but had no effect on mortality
Correct answer: A. Tranexamic acid significantly reduced death from bleeding when given within 3 hours of delivery

Explanation

The WOMAN trial (2017, Lancet) showed that tranexamic acid (1 g IV) significantly reduced death due to bleeding (risk ratio 0.81, p=0.045) when administered within 3 hours of delivery, without increasing thromboembolic events. It did not significantly reduce all-cause maternal mortality. Hysterectomy rates were not significantly different.

Reference: Williams Obstetrics, 26th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.

Sponsored

Want to test yourself?

Create a free account for timed mock tests, mistake tracking, and FSRS spaced-repetition revision across 23,000+ MCQs.

Start free → Log in

More Antepartum and Postpartum Hemorrhage MCQs

See all Antepartum and Postpartum Hemorrhage MCQs →